-
Fierce Biotech2 weeks ago
Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog for psychiatric conditions
Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its wholly owned subsidiary, Otsuka America, in a deal that could also deliver up to...
-
Fierce Biotech2 weeks ago
AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flops
AstraZeneca’s chronic obstructive pulmonary disease drug candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded...
-
Fierce Biotech2 weeks ago
Novartis pens $2B deal for allergy biotech with potential Xolair successor
Novartis has penned a $2 billion deal for a biotech whose next-gen anti-IgE program could offer a worthy successor to Xolair.
-
Fierce Biotech2 weeks ago
Chutes & Ladders—Tang takes over Aurinia after FDA brouhaha
Seasoned biotech takeover titan Kevin Tang has struck again. After serving as board chair of Aurinia since 2024, Tang has now ascended to the CEO spot...
-
Fierce Biotech2 weeks ago
CMR Surgical kicks off Versius Plus robot’s US commercial launch
Following FDA approval last December for its upgraded robot, CMR Surgical has begun rolling out its Versius Plus platform in the U.S.
-
Fierce Biotech2 weeks ago
Philips AI cath lab copilot nets FDA clearance
Developed with Edwards Lifesciences, DeviceGuide is aimed at the challenging task of transcatheter mitral valve repair.
-
Fierce Biotech2 weeks ago
‘We need to put some bad ideas to bed’: Inside Incubate’s battles for biotech on Capitol Hill
John Stanford spent a busy day on Capitol Hill this week making the case that the success of the domestic biotech industry is an issue of...
Microplastics in Human Bile Drive Mitochondrial Dysfunction and Senescence
STAT+: Health insurers score major win with higher 2027 Medicare Advantage rates
